GPC sobre Trastornos de Conducta Alimentaria (TCA)

302. McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE Jr, et al. Placebo-controlled
trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry.
2000;157(6):1004-6.
303. Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, et al. Imipramine
and diet counseling with psychological support in the treatment of obese binge eaters: a randomized,
placebo-controlled double-blind study. Int J Eat Disord. 1999;26(3):231-44.
304. McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. Citalopram in the treatment
of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry. 2003;64(7):807-13.
305. Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE Jr, Carter WP, et al. Fluvoxamine in
the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial.
Am J Psychiatry. 1998;155(12):1756-62.
306. Pearlstein T, Spurell E, Hohlstein LA, Gurney V, Read J, Fuchs C, et al. A double-blind, placebo-controlled
trial of fluvoxamine in binge eating disorder: a high placebo response. Arch
Womens Ment Health. 2003;6(2):147-51.
307. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, et al. A
randomized, double-blind, placebo-controlled study of sibutramine in the treatment of bingeeating
disorder. Arch Gen Psychiatry. 2003;60(11):1109-16.
308. Dunican KC, DelDotto D. The role of olanzapine in the treatment of anorexia nervosa. Ann
Pharmacother. 2007;41(1):111-5.
309. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term
treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta
Psychiatr Scand. 1982;66(6):445-50.
310. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A doubleblind
placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288-92.
311. Goldberg SC, Casper RC, Eckert ED. Effects of cyproheptadine in anorexia nervosa. Psychopharmacol
Bull. 1980;16:29-30.
312. Bulimia as a form of self-addiction: treatment with naltrexone hydrochloride (Trexan (TM))
- A pilot study. Clin Trials J. 1990;27:77-83.
313. Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, et al. A placebocontrolled,
double-blind crossover study of naltrexone hydrochloride in outpatients with normal
weight bulimia. J Clin Psychopharmacol. 1989;9(2):94-7.
314. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, et al. Treatment
of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial,
part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64(11):1335-41.
315. Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, et al. Treatment
of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial,
part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64(12):1449-54.
316. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, et al. Atomoxetine
in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin
Psychiatry. 2007;68(3):390-8.
317. Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, et al. Effect of
decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a
randomised, double-blind trial. Lancet. 2000;355(9206):792-7.
318. Brambilla F, García CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy
in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197-204.
319. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa:
involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402-6.
320. Timothy B, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after
weight restoration in anorexia nervosa: a randomized controlled trial. JAMA.
2008;295(22):2605-12.
290 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS